Remus Pharmaceuticals shareholders and shareholding pattern
NSE: REMUSPharmaceuticals & Biotechnology
Remus Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2023 · Issue price ₹1,229
Last close ₹843.35down ₹30.45 (3.48%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹873.80.
30 Oct: open ₹855.00, high ₹855.00, low ₹830.10
52-week range of traded prices to 30 Oct 2026
₹580.00Low, 9 Mar 2026₹1,039.00High, 15 Oct 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results, dividend and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹994 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.87
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.83
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.12%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,70066.7% delivered
Remus Pharmaceuticals' shareholding pattern for Sep 2026, filed on 21 Oct 2026, with every filing from Sep 2023: who owns its shares by group, its promoters by name and its public holders of 1% or more.
Who owns Remus Pharmaceuticals, filing by filing
Per cent of the company's shares.
Sep 2026 filing
- Promoters70.95%
- Foreign institutions5.10%
- Indian institutions0.43%
- Individuals and others23.52%
Shareholding pattern, per cent
- Promoters
- Foreign institutions
- Indian institutions
- Individuals and others
| Per cent | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|
| 69.61% | 70.60% | 70.84% | 70.85% | 70.91% | 70.95% | 70.95% | |
| Indian promoters | 69.61% | 70.60% | 70.84% | 70.85% | 70.91% | 70.95% | 70.95% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. Public in the glossary | 30.39% | 29.40% | 29.16% | 29.15% | 29.09% | 29.05% | 29.05% |
| Shares in issue | 14,73,000 | 14,73,000 | 58,92,000what Shares in issue, Sep 2024, includes. Bonus issue on 6 Jun 2024: 3 new shares for every 1 held. Earlier filings count the shares before it. | 58,92,000 | 1,17,84,000what Shares in issue, Sep 2025, includes. Bonus issue on 4 Jul 2025: 1 new share for every 1 held. Earlier filings count the shares before it. | 1,17,84,000 | 1,17,84,000 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. Shares locked in in the glossary | 10,85,000 | 10,85,000 | 11,80,000 | 11,80,000 | 23,60,000 | 23,60,000 | – |
| Promoters' shares locked in | 10,07,125 | 10,07,125 | 11,80,000 | 11,80,000 | 23,60,000 | 23,60,000 | – |
A dash is a line the filing did not state.
Remus Pharmaceuticals promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is Shah Arpit Deepakkumar, 17.66%. The filing names 35 more members with no shares.Promoter buying and selling
| Holder | ||
|---|---|---|
| Shah Arpit DeepakkumarIndividuals and Hindu undivided families | 17.66% | 20,81,200 |
| Roma Vinodbhai ShahIndividuals and Hindu undivided families | 17.21% | 20,27,800 |
| Swapnil Jatinbhai ShahIndividuals and Hindu undivided families | 16.97% | 20,00,000 |
| Anar Swapnil ShahIndividuals and Hindu undivided families | 16.97% | 20,00,000 |
| Hemant Ishwarlal ModiIndividuals and Hindu undivided families | 1.00% | 1,17,600 |
| Renosen Pharmaceuticals Private LimitedIndian companies, trusts and others | 0.92% | 1,08,500 |
| Mansi Aadarsh ShahIndividuals and Hindu undivided families | 0.07% | 8,000 |
| Sonal Hemantbhai ModiIndividuals and Hindu undivided families | 0.07% | 8,000 |
| Vinodkumar Gandalal ShahIndividuals and Hindu undivided families | 0.06% | 6,800 |
| Alkaben Dipakkumar ShahIndividuals and Hindu undivided families | 0.02% | 2,600 |
| Dhruvalben Vishal ShahIndividuals and Hindu undivided families | 0.01% | 700 |
No promoter shares are reported as pledged.
Largest public holders of Remus Pharmaceuticals, filing by filing
Per cent, on the same shares as the split above.
| Holder | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|
| India Emerging Giants Fund LimitedForeign portfolio investors, category I | – | – | – | 4.41% | 4.76% | 4.87% | 4.26% |
| Rekha Gunavanth KumarResident individuals, over ₹2 lakh at face value | 1.09% | 1.09% | 1.09% | 1.09% | 1.09% | 1.09% | 1.09% |
| Iegfl - Multi OpportunityForeign portfolio investors, category I | 2.21% | 2.84% | 2.94% | – | – | – | – |
| Chhattisgarh Investments LimitedCompanies | 2.02% | – | – | – | – | – | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.
Who moved in the Sep 2026 filing
Against the Mar 2026 filing. A filing names a public holder only at 1% or more, so a holder no longer named fell under 1% or sold out.
- Foreign institutions: India Emerging Giants Fund Limited 4.26%, −0.61 pts